Edition spéciale ISTH 2026
Annual congress of International Society on Thrombosis and Haemostasis
Du 11 au 15 juillet 2026, Paris
Avec le soutien institutionnel
Interviews
Parcours d’experts
Brèves
D’après la communication orale de D. Lillicrap « VWD – 100 years of science: What’s new after a century of investigations » (PL04.1).
D’après les communications orales de :
- E. Merriman « Risk of hormonal therapy in women with thrombophilia or a history of venous thromboembolism safety of transdermal oestrogen in women with previous history of/high risk of arterial events » (SSC 28.2)
- J. Douxfils « Oral contraceptives: Are natural estrogens safer regarding thrombosis risk? »
- J. Hugon Rodin « Alternative therapies in postmenopausal women for patients with thrombophilia or a history of venous thromboembolism? » (SSC 28.3)
- E. Grandone « Dosage and type of hormonal control ovarian stimulation and the risk for thrombosis » (SSC 28.5)
D’après la communication orale de O. Efros “Single-cell atlas of human endothelial hemostatic programs in health and cancer” (OC60.3)
D’après la communication orale de S. Buet «Predicting VWF and FVIII Response to Desmopressin Using Mechanistic Approach Model in Mild Hemophilia A and Female Carriers » (OC 66.2)
D’après la communication orale de M. Porres Aguilar “Low-dose apixaban for extended duration venous thromboembolism prevention in obese patients with cancer: post-hoc analysis of the EVE trial” (OC61.4)
D’après la communication de M. Mahmoud «Therapeutic potential of an agonistic single-domain antibody stimulating protein S in sickle cell disease» (OC70.5)
D’après la communication orale de A.Wolberg «From control to chaos: Mechanisms shaping venous thromboembolism » (PL03.1)
D’après la communication orale de S.Niraula “Impact of bariatric surgery, semaglutide, and tirzepatide on thromboembolism and ISTH majore bleeding in obese adults: A multicenter TriNetX Cohort Study” (OC51.5)
D’après la communication de L. Kühne « Management of Immune TTP without Therapeutic Plasma Exchange in Severe Episodes: Subgroup Analysis of the ATMAR and REACT-2020 Cohorts» (OC67.1)
D’après la communication orale de C. Ducker « Effects of oral anticoagulants on endothelial procoagulant phenotype in response to inflammation » (OC72.1)
D’après la communication orale de D. Samat « Long-Term Outcomes in Pregnancy-Associated Venous Thromboembolism » (OC74.2)
D’après la communication orale de S. Liu « Disruption of the β3-Src interaction exhibits safe and effective antithrombotic and immunomodulatory effects » (OC76.3)
D’après la communication orale de F. Couturaud « Development of a venous thromboembolism prediction score in first-degree relatives of affected patients: comparison with the general population » (OC73.3)
D’après la communication orale de J. Elhasnaoui « In Vitro Proof-of-concept Of A Murine Monoclonal Anti-D-dimer Antibody Conjugate For In Vivo Real Time Imaging of Thrombosis » (OC79.3)
D’après la communication orale de Y. Yang « A role for STING Protein Palmitoylation in Platelet-Mediated Thrombosis in Acute Ishemic Stroke » (OC76.4)
D’après la communication orale de I. Mahé « Recurrent venous thromboembolism during extended apixaban therapy for cancer-associated thrombosis: clinical presentation and short-term outcomes. Insights from the API-CAT proepective randomised double-blind trial » (OC41.1)
D’après les communications orales de :
- Q. Van Thillo « Sutacimig Prophylaxis in Glanzmann Thrombasthenia: Results from a Phase 2 Long-Term Extension » (OC57.3)
- M. Zivkovic « Elucidating Sutacimig’s Dual Mechanism in Factor VII Deficiency: TF-Pathway Enhancement via FVIIa Accumulation as the Significant Driver of Hemostatic Activity » (OC12.4)
D’après la communication de F. Vanhoutte « Safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of REGN9533, a monoclonal antibody targeting Factor XII (FXII), in healthy adults: Results from a Phase 1, randomised, double-blind, placebo-controlled study » (OC31.5).
D’après la communication orale de J. Whitman « Platelet FcγRIIA expression and FcγRIIA-PLCγ2 ITAM signaling regulate reperfusion injury after ischemic stroke in FCGR2A transgenic mice » (OC56.5)
D’après la communication orale de N.Juffermans « Clinical Insights from the First Human Study of BAY 3389934: A Dual Factor IIa/Xa Inhibitor » (OC31.4)
D’après la communication orale de T. Münzel « Noise, air pollution, climate change, and cardiovascular disease » (PL02.1).
D’après la communication orale de S. Mohsenian « Genotype and phenotype characterization of patients with factor X deficiency » (0C46.3).
D’après la communication orale de S. Sarojini, Ablation of Apoptosis Signal-Regulating Kinase 1 in Platelets Protects Mice from Endotoxemia (OC40.3).
D’après la communication orale de F. Couturaud « Association between pulmonary vascular obstruction phenotype and pulmonary embolism recurrence: results from the PADIS-PE study » (OC34.2).
D’après la communication orale de A. Gojoy « Heparin bridging or no bridging for patients with heart mechanic valve » (0C42.3).
D’après la communication orale de A. Guy, Antithrombotic and cytoreduction strategies in myeloproliferative neoplasm–associated splanchnic vein thrombosis: a retrospective study from the French Intergroup of Myeloproliferative Neoplasms (FIM) (OC23.1).
D’après la communication orale de G. Van de Velde, Phagocytosis of human platelets by vascular smooth muscle cells leads to a procoagulant phenotype (OC19.2).
D’après la communication orale de C. Keicher, Inno8, the first orally administered factor VIII mimetic shows favorable safety, pharmacokinetic, and pharmacodynamic properties in healthy male participants (LB02.3).
D’après la communication orale de P. Raheja, First-in-human investigation of HMB-002: a subcutaneous antibody for prophylactic management of Von Willebrand disease (OC12.5).
D’après la session orale modérée par C. James – Milka Koupenova, Origins, dynamics and fate of NETs (SOA03)
D’après la communication orale de G. Jourdi, Antiplatelet drug monitoring – when and how or not at all? different perspectives, progress and plans for related SSC project (SSC).
D’après la communication orale de S. MacKenzie, 12-Lipoxygenase Inhibition with VLX-1005 in Heparin-Induced Thrombocytopenia (LB01.1).
D’après la communication orale de S. Shivakumar « Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip or Total Knee Arthroplasty – The EPCAT III Study » (LB01.3).
D’après la communication orale de G. Jourdi, Antiplatelet drug monitoring – when and how or not at all? different perspectives, progress and plans for related SSC project (SSC).
D’après la communication orale de N. Bondil, Prescribing a museum : when culture becomes a therapeutic adjunct (Plenary).
D’après la communication orale de K. Nogami, Major Surgeries in People with Hemophilia A under NXT007 Prophylaxis: Experience from NXTAGE Phase I/II Study (OC02.3).
D’après la communication orale de A.M. Hulshof, The VWF-ADAMTS13 axis as a driver of VEXAS-associated hypercoagulability (OC10.4).
D’après la communication orale de S. Šaulytė Trakymien, Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off (OC02.1).
D’après la communication orale de A. Antony Konkoth, Galectin-9 drives platelet activation and venous thrombosis (OC10.1).
D’après la communication orale de I. Gouin Thibault & F. Mullier, Guidance on Monitoring and Management of Therapeutic-dose UFH in Practice (GG01.6).
D’après la communication orale de C. Vayne, Dynamin-related protein 1 (Drp1) phosphorylation provides a new strategy for platelet function testing in the diagnosis of HIT and VITT (OC07.2).
D’après la communication orale de A. Damara, Innate Immune Memory in Recurrent Deep Vein Thrombosis (OC10.2).
Équipe éditoriale
Rédacteur en chef
Yves GRUEL
CHRU de Tours
Rédacteurs
Alexandre Guy,
Bordeaux
Adeline Pontis,
Rennes
Jérôme Rollin,
Tours
